Mankind Pharma Limited manufactures pharmaceutical products. It offers products in the areas of antibiotics, antifungals, gastrointestinals, anthelmintics, cardiovascular products, dermal products, ophthalmic, antibacterial, acute and chronic disease, antipsychotic, veterinary, antidiabetic, hypothyroidism, cough prepration, antimalarial, antimigraine, anti-viral, steriods, opthalmic, gynaecological, and anti-asthmatics. The company also provides consumer products, such as emergency contraceptives, pregnancy detection cards, antacids, condoms, sanitary napkins, body sprays, pregnancy test kits, toothbrushes, and sweeteners. It sells its products through a network of stockists and C&F agents....
New Delhi, 110 020
Founded in 1991
Mankind Pharma Mulls Acquisitions
Dec 3 14
Mankind Pharma Limited is looking for potential acquisitions or mergers, and growth opportunities abroad.
Warburg Pincus May Buy ChrysCap's Stake In Mankind Pharma
Nov 19 14
Warburg Pincus LLC is planning to acquire the 11% stake held by ChrysCapital in Mankind Pharma Limited for about $250 million, apart from making a primary infusion. If the deal goes through, ChrysCap would make a 9x returns on its seven year old investment.
ChrysCapital Reportedly In Talks To Sell Mankind Pharma
Oct 14 14
ChrysCapital intends to sell its stake in Mankind Pharma Limited. ChrysCapital is holding talks to sell its 11% stake in Mankind Pharma. The potential buyers are all PE firms, including Temasek Holdings (Private) Limited, General Atlantic LLC, Actis Capital, LLP and Advent International Corporation. ChrysCapital hopes to fetch over $200 million for its 11% holding. Financial Services Monitor Worldwide added that Ramesh Juneja, Chief Executive Officer of Mankind, said in an email response: Regarding ChrysCapital seeking exit from Mankind you may directly speak with them because it is entirely their decision. ChrysCapital spokesperson Sanjiv Kaul declined comment.